BIT Capital GmbH Grows Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

BIT Capital GmbH boosted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 23.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 274,915 shares of the company’s stock after buying an additional 52,494 shares during the period. BridgeBio Pharma makes up about 0.6% of BIT Capital GmbH’s holdings, making the stock its 25th biggest position. BIT Capital GmbH owned approximately 0.15% of BridgeBio Pharma worth $7,544,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of BBIO. Emerald Advisers LLC increased its stake in shares of BridgeBio Pharma by 4.3% during the fourth quarter. Emerald Advisers LLC now owns 1,150,868 shares of the company’s stock worth $31,580,000 after acquiring an additional 47,360 shares during the period. Vanguard Group Inc. increased its position in BridgeBio Pharma by 6.2% during the 4th quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company’s stock worth $413,738,000 after purchasing an additional 879,059 shares during the period. KLP Kapitalforvaltning AS acquired a new position in BridgeBio Pharma during the 4th quarter worth approximately $692,000. American Century Companies Inc. raised its stake in shares of BridgeBio Pharma by 9.6% during the 4th quarter. American Century Companies Inc. now owns 1,015,728 shares of the company’s stock worth $27,872,000 after buying an additional 88,882 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its holdings in shares of BridgeBio Pharma by 28.6% in the 4th quarter. Teacher Retirement System of Texas now owns 36,208 shares of the company’s stock valued at $994,000 after buying an additional 8,048 shares during the period. Hedge funds and other institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Stock Performance

Shares of NASDAQ:BBIO opened at $36.10 on Thursday. The business’s fifty day moving average price is $34.19 and its two-hundred day moving average price is $29.21. The stock has a market cap of $6.87 billion, a PE ratio of -12.67 and a beta of 1.07. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The company had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million. As a group, equities research analysts predict that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $32.96, for a total transaction of $197,760,000.00. Following the transaction, the insider now directly owns 19,260,971 shares in the company, valued at approximately $634,841,604.16. This represents a 23.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Global Investors Lp Viking sold 3,065,616 shares of BridgeBio Pharma stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $34.90, for a total value of $106,989,998.40. Following the completion of the sale, the insider now owns 22,055,375 shares of the company’s stock, valued at $769,732,587.50. This trade represents a 12.20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 9,579,739 shares of company stock valued at $323,171,901 over the last 90 days. Insiders own 24.66% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on BBIO shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $95.00 price objective on shares of BridgeBio Pharma in a research report on Friday, February 21st. HC Wainwright reiterated a “buy” rating and issued a $49.00 price target on shares of BridgeBio Pharma in a report on Thursday, February 13th. Evercore ISI raised their price objective on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research note on Monday, December 23rd. Scotiabank upped their target price on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Friday, February 21st. Finally, Citigroup lifted their price target on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Friday, February 21st. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $52.90.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.